Anti-MUC1 aptamers: radiolabelling with 99mTc and biodistribution in MCF-7 tumour-bearing mice

Nuclear Medicine and Biology

Volumn 36, Issue 6, 2009, Pages 703-710

  Pieve, Chiara Da ^a   Perkins, Alan C ^b   Missailidis, Sotiris ^a  

^a OPEN UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

99mTc; Aptamers; Biodistribution studies; FID binding assay; Glycosylated MUC1; MAG2; MCF7 tumour

Indexed keywords

MUCIN 1; SUCCIMER APTAMER A TC 99M; SUCCIMER APTAMER B TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BREAST CANCER; CELL STRAIN MCF 7; CONJUGATION; CONTROLLED STUDY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ISOTOPE LABELING; MOUSE; NONHUMAN; TISSUE DISTRIBUTION;

ANIMALS; APTAMERS, NUCLEOTIDE; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; FLUORESCENT DYES; HUMANS; INTERCALATING AGENTS; ISOTOPE LABELING; MICE; MUCIN-1; ORGANOTECHNETIUM COMPOUNDS; TISSUE DISTRIBUTION;

EID: 67651162036     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.04.004     Document Type: Article

References (34)

1. von Mensdorff-Pouilly S., Snijdewint F.G., Verstraeten A.A., Verheijen R.H., and Kenemans P. Human MUC1 mucin: a multifaceted glycoprotein. Int J Biol Markers 15 (2000) 343-356
2. Gendler S.J. MUC1, the renaissance molecule. J Mammary Gland Biol Neoplasia 6 (2001) 339-353
3. Limacher J.M., and Acres B. MUC1, a therapeutic target in oncology. Bull Cancer 94 (2007) 253-257
4. Singh R., and Bandyopadhyay D. MUC1: a target molecule for cancer therapy. Cancer Biol Ther 6 (2007) 481-486
5. Taylor-Papadimitriou J., Burchell J.M., Plunkett T., Graham R., Correa I., Miles D., et al. MUC1 and the immonology of cancer. J Mammary Gland Biol Neoplasia 7 (2002) 209-221
6. Leroy X., Buisine M.P., Leteurtre E., Aubert S., Buob D., Porchet N., et al. MUC1 (EMA): a key molecule of carcinogenesis?. Ann Pathol 26 (2006) 257-266
7. Apostopoulos V., Pietersz G.A., and McKenzie I.F.C. MUC1 and breast cancer. Curr Opin Mol Ther 1 (1999) 98-103
8. Yang E., Hu X.F., and Xing P.X. Advances of MUC1 as a target for breast cancer immonotherapy. Histol Histopathol 22 (2007) 905-922
9. Buchegger F., Press O.W., Bischof Delaloye A., and Ketterer N. Radiolabeled and native antibodies and the prospect of cure of follicular lymphoma. The Oncologist 13 (2008) 657-667
10. Hagenbeek A. Radioimmunotherapy for NHL: Experience of 90Y-ibritumomab tiuxetan in clinical practice. Leukemia & Lymphoma 44 (2002) S37-S47
11. Burke J.M., Jurcic J.G., and Scheinberg D.A. Radioimmunotherapy for acute leukemia. Cancer Control 9 (2002) 106-113
12. Jayasena S.D. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 45 (1999) 1628-1650
13. Khan H., and Missailidis S. Aptamers in oncology: a diagnostic perspective. Gene Ther Mol Bio 12 (2008) 111-128
14. Brody E.N., and Gold L. Aptamers as therapeutic and diagnostic agents. Rev Mol Biotechnol 74 (2000) 5-13
15. Ferreira C.S.M., and Missailidis S. Aptamer-based therapeutics and their potential in radiopharmaceutical design. Braz Arch Biol Tech 50 (2007) 63-76
16. Tavitian B. In vivo imaging with oligonucleotides for diagnosis and drug development. Gut 52 (2006) 40-47
17. Mayer G., and Jenne A. Aptamers in research and drug development. Biodrugs 18 (2004) 351-359
18. Cerchia L., Hamm J., Libri D., Tavitian B., and de Franciscis V. Nucleic acid aptamers in cancer medicine. FEBS Lett 528 (2002) 12-16
19. Perkins A.C., and Missailidis S. Radiolabelled aptamers for tumour imaging and therapy. Q J Nucl Med Mol Imaging 51 (2007) 292-296
20. Hicke B.J., Stephens A.W., Gould T., Chang Y.F., Lynott C.K., Heil J., et al. Tumor targeting by an aptamer. J Nucl Med 47 (2006) 668-678
21. Borbas K.E., Ferreira C.S.M., Perkins A., Bruce J.I., and Missailidis S. Design and synthesis of mono- and multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. J Bioconjugate Chem 18 (2007) 1205-1212
22. Ferreira C.S.M., Matthews C.S., and Missailidis S. DNA aptamers that bind to MUC1 tumour marker: design and characterization of MUC1-binding single-stranded DNA aptamers. Tumor Biol 27 (2006) 289-301
23. Gariepy J., Ferreira C.S.M., and Missailidis S. Aptamers directed to recombinant MUC1 (2007) WIPO patent WO2007129114
24. Friedman A.E., Chambron J.C., Sauvage J- P., Turro N.J., and Barton J.K. Molecular "light switch" for DNA: Ru(bpy)2(dppz)2+. J Am Chem Soc 112 (1990) 4960-4962
25. Hiort C., Lincoln P., and Norden B. DNA binding of d- and l-[Ru(phen)2DPPZ]2+. J Am Chem Soc 115 (1993) 3448-3454
26. Moon S.J., Kim J.M., Choi J.Y., Kim S.K., Lee J.S., and Jang H.G. [Ru(phen)2DPPZ]2+ is in contact with DNA bases when it forms a luminescent complex with single-stranded oligonucleotides. J Inorg Biochem 99 (2005) 994-1000
27. Brigui I., Dijavanbakht-Samani T., Jolles B., Pigaglio S., and Laigle A. Minimally modified phosphodiester antisense oligodeoxyribonucleotide directed against the multidrug resistance gene mdr 1. Biochem Pharmacol 65 (2003) 747-754
28. Hnatowich D.J., Virzi F., Fogarasi M., Winnard Jr. P., and Rusckowski M. Can a cysteine challenge assay predict the in vivo behavior of 99mTc-labeled antibodies?. Nucl Med Biol 21 (1994) 1035-1044
29. Hjelstuen O.K., By B.C., Cleynhens B., Ormstad H.M., Roald T.E., Tønnesen H.H., et al. Comparative evaluation of 99mTc-MAG2-oligodeoxynucleotides with phosphodiester or phosphorothioate backbones: preparation, stability and biodistribution. J Labelled Cpd Radiopharm 42 (1999) 737-760
30. Zhang Y.M., Liu N., Zhu Z.H., Rusckowski M., and Hnatowich D.J. Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA. Eur J Nucl Med 27 (2000) 1700-1707
31. Ruckman J., Green L.S., Beeson J., Waugh S., Gillette W.L., Henninger D.D., et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165). J Biol Chem 273 (1998) 20556-20567
32. Willis M.C., Collins B., Zhang T., Green L.S., Sebesta D.P., Bell C., et al. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjugate Chem 9 (1998) 573-582
33. Farokhzad O.C., Jon S., Khademhosseini A., Tran T.N.T., LaVan D.A., and Langer R. Nanoparticle-aptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 64 (2004) 7668-7672
34. De Lean A., Munson P.J., and Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol 235 (1978) E97-E102